NFKB1 and COVID-19: Another study by Kircheis et al. [9], which investigated therapeutic approaches which aim at inhibiting the whole cascade of proinflammatory cytokines and chemokines, revealed that some proteasome inhibitors (carfilzomib or ixazomib) are regarded as powerful biomarkers for NF‐κB inhibition, downregulating cytokine storm in COVID‐19 patients.